Immunity to Measles Virus in the Thai Population Age 18-30 Years and Predictive Factors
NCT01602094 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 550
Last updated 2012-05-18
Summary
Prevalence of participants who have protective immunity to measles virus is less than ninety percent.
Predictor of adequate measles antibody levels include the following :
* History of measles infection
* History of complete measles primary immunization( 2 doses with at least 1 month interval after age of 9 months)
* History of measles exposure
Predictor of inadequate measles antibody levels include the following :
* Born outside Thailand
* History of staying outside Thailand for long time in childhood
* Living in the rural area for a long period in childhood
* Fail to participate school system on time
Conditions
Sponsors & Collaborators
-
Queen Saovabha Memorial Institute
lead OTHER
Principal Investigators
-
Jaruboot Angsanakul, M.D. · Queen Saovabha Memorial Institute
Eligibility
- Min Age
- 18 Years
- Max Age
- 30 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2012-07-31
- Primary Completion
- 2013-01-31
- Completion
- 2013-03-31
Countries
- Thailand
Study Locations
More Related Trials
-
Measles, Mumps, and Rubella (MMR) Immunity in College Students
NCT00962819 ·Status: COMPLETED
-
Long-term Follow-up of Measles Antibodies
NCT00168571 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years
NCT00891007 ·Status: COMPLETED ·Phase: PHASE2
-
Measles Vaccination at Health System Contacts
NCT04220671 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE4
-
Induction of Immunity Against Measles in Pediatric Liver Transplant Recipients
NCT01770119 ·Status: RECRUITING ·Phase: PHASE4
-
Unravelling the Measles Paradox in Children
NCT06923631 ·Status: NOT_YET_RECRUITING
-
Immunology of Non-specific Effects of Vaccine
NCT00168545 ·Status: COMPLETED ·Phase: PHASE4
-
Non-specific Effects of a Modified Measles Vaccination Schedule to Prevent Allergy and Unrelated Infection in Children
NCT05758532 ·Status: RECRUITING ·Phase: PHASE4
-
Earlier Prime-BOOST Schedule to Improve MEasles Protection in High Burden Settings
NCT06667206 ·Status: RECRUITING ·Phase: PHASE2
-
Investigation of Immune Amnesia Following Measles Infection in Select African Regions
NCT06153979 ·Status: COMPLETED
-
Trial of Additional Measles Vaccine to Reduce Child Mortality
NCT01644721 ·Status: COMPLETED ·Phase: PHASE4
-
Unravelling the Measles Paradox (MISIA)
NCT07267585 ·Status: RECRUITING
-
The Effect on Overall Mortality of a National Policy of Limiting Measles Vaccination to Children Below 12 Months of Age
NCT01306006 ·Status: COMPLETED ·Phase: PHASE4
-
Prophylactic Antibiotics in Measles
NCT00168532 ·Status: COMPLETED ·Phase: PHASE3
-
Impact of HIV on Measles and Measles Immunisation
NCT00247091 ·Status: COMPLETED
-
Additional Measles Vaccine at 4 Months of Age
NCT01486355 ·Status: UNKNOWN ·Phase: PHASE4
-
Secondary Attack Rate Measles Vaccine In Second Situation Contacts Cases Confirmed
NCT05592756 ·Status: COMPLETED
-
Early Two-dose Measles Vaccination Trial
NCT00168558 ·Status: COMPLETED ·Phase: PHASE4
-
Barriers and Facilitators to MMR Vaccination Among Healthcare Workers
NCT06456788 ·Status: COMPLETED
-
Measles Vaccine: Is There a Protective Role in COVID 19 Pandemic?
NCT04445610 ·Status: UNKNOWN
-
A Clinical Trial to Assess the Safety of a Measles Vaccine (Dry Powder) Administered by Two Different Devices
NCT01557699 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Assess Efficacy and Safety of M72/AS01E-4 Mycobacterium Tuberculosis (Mtb) Vaccine in Adolescents and Adults
NCT06062238 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years
NCT00161863 ·Status: COMPLETED ·Phase: PHASE3
-
Measles and BCG Vaccines for Mother and Child
NCT04899765 ·Status: RECRUITING ·Phase: PHASE4
-
Vaccine Campaign Effects on General Hospital Admissions and Mortality Among Children
NCT03460002 ·Status: COMPLETED ·Phase: PHASE4